Jpmorgan Chase & CO Poseida Therapeutics, Inc. Transaction History

Jpmorgan Chase & CO

$1.14 Trillion
Q2 2024

A detailed history of Jpmorgan Chase & CO transactions in Poseida Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 30,163 shares of PSTX stock, worth $76,312. This represents 0.0% of its overall portfolio holdings.

Number of Shares

30,163

Previous 78,525 61.59%

Holding current value

$76,312

Previous $250,000 64.8%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	SELL	$2.0 - $3.46 $96,724 - $167,332	-48,362 Reduced 61.59%	30,163 $88,000
Q1 2024 May 10, 2024	BUY	$2.76 - $4.13 $89,429 - $133,820	32,402 Added 70.25%	78,525 $250,000
Q4 2023 Feb 12, 2024	SELL	$1.83 - $3.51 $30,689 - $58,862	-16,770 Reduced 26.66%	46,123 $154,000
Q3 2023 Nov 14, 2023	BUY	$1.62 - $2.79 $8,841 - $15,227	5,458 Added 9.5%	62,893 $149,000
Q2 2023 Aug 11, 2023	BUY	$1.66 - $3.4 $92,438 - $189,332	55,686 Added 3183.88%	57,435 $101,000
Q1 2023 May 11, 2023	SELL	$3.08 - $8.73 $90,783 - $257,316	-29,475 Reduced 94.4%	1,749 $5,000
Q4 2022 Feb 13, 2023	SELL	$3.33 - $6.38 $272,936 - $522,923	-81,963 Reduced 72.41%	31,224 $165,000
Q3 2022 Nov 14, 2022	SELL	$2.43 - $4.51 $294,022 - $545,696	-120,997 Reduced 51.67%	113,187 $400,000
Q2 2022 Aug 11, 2022	SELL	$1.87 - $5.0 $158,000 - $422,460	-84,492 Reduced 26.51%	234,184 $604,000
Q1 2022 May 11, 2022	BUY	$3.22 - $7.04 $67,278 - $147,093	20,894 Added 7.02%	318,676 $1.43 Million
Q4 2021 Feb 10, 2022	SELL	$6.23 - $7.6 $350,643 - $427,750	-56,283 Reduced 15.9%	297,782 $2.03 Million
Q3 2021 Nov 12, 2021	BUY	$7.09 - $10.71 $2.51 Million - $3.79 Million	354,065 New	354,065 $2.58 Million

Others Institutions Holding PSTX

# of Institutions

Shares Held

38.2M

Call Options Held

417K

Put Options Held

42.7K

View Full List

About Poseida Therapeutics, Inc.

Ticker PSTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 85,775,600
Market Cap $217M
Description
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant ...

More about PSTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Poseida Therapeutics, Inc. Transaction History